Please join us on the 7th June 2022, from 10:00 – 11:30 CEST to learn about Olink’s PEA technology for human proteomic analysis, listen to a case study on oncology and hear from Dr Stefan Enroth from Uppsala University, Sweden about “High-precision biomarkers for Ovarian Cancer: Experiences with Olink Explore”.
What you will learn from this webinar:
Swedish Collegium for Advanced Study, Uppsala.
Department of Immunology, Genetics and Pathology, Uppsala University, SwedenSandra Kyrk
Business Development Manager
Olink
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.